Shares of crop gene editing pioneer firm Cibus Global Ltd. have tumbled to a 52-week low, with the stock price touching down at $1.8, marking a significant downturn for the company. This latest price level reflects a stark contrast to the stock’s performance over the past year, with Cibus Global witnessing a precipitous 1-year change of -90.96%. [GMW comment: Cibus has been promoted by pro-GMO lobbyists as an industry leader for new GMO (gene-edited) crops. But there have been reports that Cibus is being investigated for deceiving investors with over-hyped claims.] Investing.com

 

 

With the second largest award of nearly $2.1 billion, a jury in Georgia state court on March 21 found the pesticide manufacturer Bayer/Monsanto guilty of causing a man’s non-Hodgkin’s lymphoma after use of the company’s glyphosate-based weedkiller Roundup. The jury’s award includes $65 million in compensatory and $2 billion in punitive damages, as reported by the Associated Press and Courtroom View Network. This verdict in Barnes v. Monsanto (2025) comes amid a concerted effort by Bayer and other chemical and agribusiness groups to take away the main legal argument, “failure-to-warn”, for the type of litigation that pesticide exposure victims have commonly used to hold companies accountable. This is happening as Governor Brian Kemp of Georgia considers signing into state law a pesticide immunity bill that will prevent future litigation like this in the state. Beyond Pesticides

 

 

Read our latest Review, on "new GMO" deregulation battles. Don't miss out – subscribe or update your subscription here. GMWatch

 

We hope you’ve found this newsletter interesting. Please support our work with a one-off or regular donation. Thank you!